Market closedNon-fractional
Nkarta/NKTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Nkarta
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
Ticker
NKTX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
South San Francisco, United States
Employees
150
Website
www.nkartatx.com
Nkarta Metrics
BasicAdvanced
$487M
Market cap
-
P/E ratio
-$2.35
EPS
0.89
Beta
-
Dividend rate
Price and volume
Market cap
$487M
Beta
0.89
Financial strength
Current ratio
19.955
Quick ratio
19.766
Long term debt to equity
18.405
Total debt to equity
18.405
Management effectiveness
Return on assets (TTM)
-15.07%
Return on equity (TTM)
-28.33%
Valuation
Price to book
1.03
Price to tangible book (TTM)
1.03
Price to free cash flow (TTM)
-2.911
Growth
Earnings per share change (TTM)
-5.72%
3-year earnings per share growth (CAGR)
-17.27%
What the Analysts think about Nkarta
Analyst Ratings
Majority rating from 9 analysts.
Nkarta Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$30M
6.50%
Profit margin
0.00%
NaN%
Nkarta Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.68
-$0.52
-$0.57
-$0.58
-
Expected
-$0.68
-$0.67
-$0.59
-$0.56
-$0.44
Surprise
0.00%
-22.82%
-3.59%
3.84%
-
Nkarta News
AllArticlesVideos
Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus
GlobeNewsWire·3 days ago
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
GlobeNewsWire·2 weeks ago
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nkarta stock?
Nkarta (NKTX) has a market cap of $487M as of July 26, 2024.
What is the P/E ratio for Nkarta stock?
The price to earnings (P/E) ratio for Nkarta (NKTX) stock is 0 as of July 26, 2024.
Does Nkarta stock pay dividends?
No, Nkarta (NKTX) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Nkarta dividend payment date?
Nkarta (NKTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Nkarta?
Nkarta (NKTX) has a beta rating of 0.89. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Nkarta stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.